PATENT CLAIM ANALYSIS

Application Number: 15990524
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["514", "019300"]

Abstract:
T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.

Claim (Index 8):
The modified T cell receptor of  claim 2 , wherein the modified T cell receptor comprises an amino acid substitution at one or more of CDR3\u03b1 92, CDR3\u03b1 100, CDR3\u03b1 101, CDR3\u03b1 102, and CDR3\u03b1 103.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.41935
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15037485', '13500123', '14813782', '15327984', '13946313']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.820490995169518
- 35 USC 102 Novelty (BERT): 0.6156310609692556
- Combined Prediction Score: 0.8000050017494917
- Mean Citation Score: 453.161688
- Max Citation Score: 624.79297
- Similarity Product: 483.0009413855897

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test